Tuesday, August 6, 2019 - Government officials in the White House and Congress are dealing with several key issues in their fight to wipe out HIV and to end the AID epidemic. First of all, Congress is battling with Truvada's CEO Daniel O'Day over the high price of the drug. A single month of one daily dose of the drug can cost a person over $20,000 per year in the US when the drug is being made available for under $100 per month in other countries. Gilead Scientific, maker of Truvada holds a virtual monopoly on Truvada by controlling its patent, even though the rights are being challenged on the grounds that the drug was discovered and developed using taxpayer funds provided by the Center for Disease Control (CDC) and the National Institute of Health (NIH). Congressman Elijah Cummings and Alexandra Cortes have accused Gilead of exploiting the HIV crisis for their own gain and keeping the drug out of the hands of the public. The drug is financially out of reach for most people that do not have health insurance or those that have policies with high co-pay or high deductibles. Also, the pre-treatment and follow up testing costs around $400 per month and that amount is usually not covered by insurance. Truvada broken bones lawyers offer individuals and families of the help and guidance with a free consultation and no obligation before filing a claim.
Second, nothing has been done to date to address the special needs of gay black and Latino teenagers, a demographic that makes up the highest percentage of new cases of HIV every year. 18-22-year-old black and Latino gay men report a disproportionate number of new HIV cases each year. "An estimated 1,122,900 people had HIV at the end of 2015. Black/African American gay and bisexual men accounted for 19% (218,600) of all people with HIV and 32% of all gay and bisexual men with HIV" according to the CDC. Making this particular group of young adults aware of the seriousness of the HIV/AIDS epidemic and convincing them that they must take the drug is the key to turning the corner and stop the spread of the disease.
Last but not least, Truvada also has the nasty side effect of causing bone density loss and experts are unsure if this condition could be reversed in individuals that take Truvada for more than one year. Legal experts agree that Gilead may have deliberatively withheld another drug, Descovy, from the market for up to a decade in order to maximize Truvada's profits for the company at the expense of making the treatment safer and more affordable. If you or a loved one have taken Truvada and have experienced bone density loss you may be entitled to real monetary compensation. Fragile bone fracture and bread easily and osteoporosis is one of the world's most dreaded diseases. Taking Truvada could amount to merely swapping one life-threatening condition for another.
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four talcum powder ovarian cancer lawsuits in St. Louis to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.